Company intelligence / Profile preview

Bach Pharma, Inc.

North Andover, Massachusetts, United Statesbachpharma.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Bach Pharma develops novel small molecule therapeutics targeting oxidative stress and inflammation pathways. Their lead candidate GVT® has shown significant preclinical efficacy in reversing oxidative stress and restoring redox homeostasis. The company focuses on severe neurodegenerative disorders like ALS and Parkinson's disease. A related compound (Galavit®, a form of monosodium luminol) has been approved outside the US for immune-related conditions with a strong safety profile. Clinical development of GVT® for rare neurological diseases in the US remains at an early stage.[1][2][3]

Therapeutic areas: OtherImmunologyNeurologyWomen's Health
Modalities: small molecules (notably phthalazinedione-based therapeutics and cytoprotective agents)[1][2][4]
Industry: Biotech

Drug pipeline

1 asset

GVT

Preclinical

Beyond the preview

Go deeper on Bach Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bach Pharma, Inc..

Explore the full profile